COMP <GO>
INCY vs ABBV // FORWARD P/E MULTIPLE
Incyte Corp. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INCY 11
— ABBV 4
▲ FORWARD P/E MULTIPLE LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
forward-pe
15.5x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | 70.20% | +22.60 | INCY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 29.00% | +13.40 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 33.3x | -20.80 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 3.47% | +1.52 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 24.60% | +4.90 | INCY | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 6.90% | +18.10 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 8.60% | +12.60 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 5.33 | +4.71 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | INCY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 72.8 | -15.27 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 15.5x | 113.1x | -97.60 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $513.86B | -$490.18B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | ABBV REV | INCY GROSS % | ABBV GROSS % | INCY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $61.16B | 92.8% | 70.2% | $1.18B | $17.82B |
| FY 2024 | $4.24B | $56.33B | 92.6% | 70.0% | $144.5M | $17.83B |
| FY 2023 | $3.70B | $54.32B | 44.0% | 44.0% | $330.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
ABBV // BETA 1.15